Sugi Predict

Sugi Predict / Compounds / SCHEMBL38711

SCHEMBL38711

SCHEMBL38711

CCCCC(CC)COC(=O)C(C(=O)OCC(CC)CCCC)c1ccc(OC)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.62
▸ ALDH1A1 P00352 5/20 0.57
▸ CYP3A4 P08684 3/20 0.57
▸ CA2 P00918 1/20 0.57
▸ LMNA P02545 3/20 0.52
▸ PRSS1 P07477 1/20 0.51
▸ PRSS2 P07478 1/20 0.51
▸ PRSS3 P35030 1/20 0.51
▸ TSHR P16473 3/20 0.49
▸ ATM Q13315 1/20 0.49
▸ MAPK1 P28482 3/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ RECQL P46063 1/20 0.45
▸ FAAH O00519 1/20 0.43
▸ TAS1R3 Q7RTX0 1/20 0.42
▸ TAS1R1 Q7RTX1 1/20 0.42
▸ MMP9 P14780 1/20 0.41
▸ MMP13 P45452 1/20 0.41
▸ MMP1 P03956 2/20 0.40
▸ MMP2 P08253 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL490512 0.88 TDP1 (0.61) TDP1ALDH1A1CYP3A4CA2LMNA
SCHEMBL490575 0.87 TDP1 (0.60) TDP1ALDH1A1CYP3A4CA2LMNA
SCHEMBL156736 0.82 TDP1 (0.60) TDP1ALDH1A1CYP3A4CA2LMNA
SCHEMBL29970780 0.82 TDP1 (0.60) TDP1ALDH1A1CYP3A4CA2LMNA
SCHEMBL31319550 0.80 ALDH1A1 (0.49) TDP1ALDH1A1CYP3A4CA2LMNA
SCHEMBL490723 0.78 TDP1 (0.53) TDP1ALDH1A1CYP3A4CA2LMNA
SCHEMBL490514 0.78 TDP1 (0.59) TDP1ALDH1A1CYP3A4CA2LMNA
SCHEMBL29176452 0.78 TDP1 (0.56) TDP1ALDH1A1CYP3A4CA2LMNA
SCHEMBL12919004 0.78 TDP1 (0.55) TDP1ALDH1A1CYP3A4CA2LMNA
SCHEMBL29480051 0.77 TDP1 (0.58) TDP1ALDH1A1CYP3A4CA2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 441 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180280343-A1 TOPICAL SILIBININ FORMULATIONS AND USES THEREFOR NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-10-04 — — US claimed
US-9232785-B2 Method for reducing sunburn damage in plants BASF SE (DE) 2016-01-12 — — US claimed
US-9011826-B2 Cosmetic and dermatological formulations including isononyl benzoate EVONIK DEGUSSA GMBH (DE) 2015-04-21 — — US claimed
US-8748347-B2 Method for combating harmful fungi BASF SE (DE) 2014-06-10 — — US claimed
US-20120083497-A1 Method for Combating Harmful Fungi BASF SE (DE) 2012-04-05 — — US claimed
EP-2418944-A2 METHOD FOR COMBATING HARMFUL FUNGI BASF SE (DE) 2012-02-22 — — EP claimed
EP-2413691-A2 METHOD FOR REDUCING SUNBURN DAMAGE IN PLANTS BASF SE (DE) 2012-02-08 — — EP claimed
US-20120017503-A1 METHOD FOR REDUCING SUNBURN DAMAGE IN PLANTS BASF SE (DE) 2012-01-26 — — US claimed
WO-2010115721-A2 METHOD FOR REDUCING SUNBURN DAMAGE IN PLANTS BASF SE (DE) 2010-10-14 — — WO claimed
WO-2010115720-A2 METHOD FOR COMBATING HARMFUL FUNGI BASF SE (DE) 2010-10-14 — — WO claimed
US-20100068160-A1 COSMETIC AND DERMATOLOGICAL FORMULATIONS INCLUDING PHENOXYALKYL ESTERS EVONIK GOLDSCHMIDT GMBH (DE) 2010-03-18 — — US claimed
US-20090136437-A1 COSMETIC AND DERMATOLOGICAL FORMULATIONS INCLUDING ISONONYL BENZOATE EVONIK GOLDSCHMIDT GMBH (DE) 2009-05-28 — — US claimed
EP-3801448-B1 WAX DISPERSIONS WITH CONDITIONING PROPERTIES BASF SE (DE) 2024-07-10 — — EP disclosed
WO-2024126115-A1 AGROCHEMICAL FORMULATIONS BASF SE (DE) 2024-06-20 — — WO disclosed
EP-4366690-A1 POLYOL ESTER MIXTURE FOR USE AS VASELINE SUBSTITUTE BASF SE (DE) 2024-05-15 — — EP disclosed
US-20240092728-A1 HYDROXY-SUBSTITUTED SPHINGOLIPIDS EVONIK OPERATIONS GMBH (DE) 2024-03-21 — — US disclosed
WO-2003005982-A1 PRODUCTS COMPRISING A SHEET AND A LIPID AND AQUEOUS PHASE JOHNSON & JOHNSON GMBH (DE) 2003-01-23 — — WO disclosed
WO-2003005983-A1 DRY PRODUCTS COMPRISING A SHEET AND TWO PHASES JOHNSON & JOHNSON GMBH (DE) 2003-01-23 — — WO disclosed
EP-1275370-A1 Products comprising a sheet and a lipid and aqueous phase Johnson and Johnson GmbH (DE) 2003-01-15 — — EP disclosed
EP-1275371-A1 Dry products comprising a sheet and two phases Johnson and Johnson GmbH (DE) 2003-01-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120017503-A1 METHOD FOR REDUCING SUNBURN DAMAGE IN PLANTS UNG, ERCC5, ERCC4 TDP1 1081/4885ALDH1A1 682/4885CYP3A4 1068/4885
US-20090136437-A1 COSMETIC AND DERMATOLOGICAL FORMULATIONS INCLUDING ISONONYL BENZOATE C1R, POLR1C, C1S TDP1 314/4885ALDH1A1 510/4885CYP3A4 3140/4885
US-20240092728-A1 HYDROXY-SUBSTITUTED SPHINGOLIPIDS SPTLC1, ASAH2, ASAH1 TDP1 452/4885ALDH1A1 1313/4885CYP3A4 4427/4885
US-20100068160-A1 COSMETIC AND DERMATOLOGICAL FORMULATIONS INCLUDING PHENOXYALKYL ESTERS CUTA, DECR2, TYR TDP1 3701/4885ALDH1A1 419/4885CYP3A4 970/4885
US-20120083497-A1 Method for Combating Harmful Fungi BROX, CRY1, GUSB TDP1 1494/4885ALDH1A1 2453/4885CYP3A4 1915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.